Pernix Therapeutics to Report First Quarter 2016 Financial Results on Thursday, May 5, 2016

MORRISTOWN, N.J., April 28, 2016 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX), a specialty pharmaceutical company, announced today that it will release financial results for the first quarter ended March 31, 2016, before the market opens on Thursday, May 5, 2016.  Doug Drysdale, Chairman and Chief Executive Officer, and Sanjay Patel, Chief Financial Officer, will host a conference call to discuss the results, as follows.

Date:	Thursday, May 5
Time:	8:30 AM EST
Toll free (U.S.):	888-312-9865
International:	719-457-2605
Webcast (live and replay):	http://public.viavid.com/index.php?id=119195

About Pernix Therapeutics Pernix Therapeutics is a specialty pharmaceutical business with a focus on acquiring, developing and commercializing prescription drugs primarily for the U.S. market. The Company targets underserved therapeutic areas such as CNS, including neurology and psychiatry, and has an interest in expanding into additional specialty segments. The Company promotes its branded products to physicians through its Pernix sales force, uses contracted sales organizations to market its non-core, cough and cold products, and markets its generic portfolio through its wholly owned subsidiaries, Macoven Pharmaceuticals, LLC and Cypress Pharmaceutical, Inc.

To learn more about Pernix Therapeutics, visit www.pernixtx.com.

Investor Relations
Sanjay Patel, (800) 793-2145 ext. 1009
Chief Financial Officer   
[email protected]   

Matthew P. Duffy, 212.915.0685
LifeSci Advisors, LLC
[email protected]

Source: Pernix Therapeutics Holdings, Inc.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Benchmark on Take-Two's (TTWO) GTV 6 Release: 'we anticipate that the game will not be released within the fiscal year and expect it to launch in fiscal 2026 instead'
• TD Cowen Reiterates Buy Rating on Constellation Brands (STZ)
• Senesco Technologies, Inc. (SNT) Reports Q1 EPS of $0.02